A Comparison of 68Ga-PSMA PET/CT-Based Split Renal Function with 99mTc-MAG3 Renography in Patients with Metastatic Castration-Resistant Prostate Carcinoma Treated with 177Lu-PSMA

Lerato Gabela,Thokozani Mkhize,Bawinile Hadebe,Lerwine Harry,Thembelihle Nxasana,Nontobeko Ndlovu,Venesen Pillay,Sphelele Masikane,Maryam Patel,Nozipho Elizabeth Nyakale,Mariza Vorster
DOI: https://doi.org/10.3390/diagnostics14060578
IF: 3.6
2024-03-09
Diagnostics
Abstract:Background: Physiological PSMA expression in the cells of the proximal renal tubules and consecutive radiopharmaceutical binding and retention could potentially lead to radioligand-therapy-induced nephrotoxicity. Thus, patients with metastatic castration-resistant prostate cancer undergo 99mTc-Mercaptoacetyltriglycine (MAG3) renal scintigraphy to assess kidney function and to exclude renal obstruction as part of their workup for PSMA-targeted radioligand therapy (RLT). 99mTc-MAG-3 renal scintigraphy often requires an additional visit to the nuclear medicine department and patients spend 30–90 min in the department, which is inconvenient and takes up camera time. In addition, the patients are subjected to a baseline 68Ga-PSMA PET/CT to assess for PSMA-positive disease prior to targeted radioligand therapy. The aim of this retrospective cross-sectional study was to compare 99mTc-MAG-3-based split renal function (SRF) with 68Ga-PSMA-derived SRF. Methods: This retrospective cross-sectional study included 28 patients with histologically proven metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA617. A comparison between the split renal function using 68Ga-PSMA PET/CT and the 99mTc-MAG-3-derived split renal function was carried out in 56 kidneys (n = 56). The SRF on 68Ga-PSMA was calculated using the volume and the average standard uptake value (SUVmean) within each VOI calculated as previously described by Roser et al.: SRF = (VOLUMEright) ∗ SUVmeanright/(VOLUMEright ∗ SUVmeanright + VOLUMEleft ∗ SUVmeanleft). Paired tests and correlation coefficients were used to compare 68Ga-PSMA and 99mTc-MAG-3. A visual comparison of kidney morphology on both studies was also performed. Results: The median SRF of the right kidney was 49.9% (range: 3–91%) using 68Ga-PSMA PET/CT and 50.5% (range: 0–94%) with 99mTc-MAG3 scintigraphy. Notably, there was a strong correlation between SRF measurements obtained from PSMA and 99mTcMAG3, with a Pearson correlation coefficient of 0.957 (p < 0.001). Both 99mTc-MAG3 and 68Ga-PSMA PET/CT studies identified morphological renal abnormalities; there were nine hydronephrotic kidneys, four shrunken kidneys and one obstructed kidney, and there was a strong positive correlation between 68Ga-PSMA kidney morphology and 99mTcMAG3 renal scintigraphy kidney morphology, with a correlation coefficient of 0.93. Conclusions: PSMA-derived split function demonstrated a high correlation with renal function assessed on diuretic 99mTc-MAG3 renograms. PET-derived split renal function may, therefore, be considered an alternative to diuretic renogram-based split function. Furthermore, both 99mTc-MAG3 and 68Ga-PSMA PET/CT studies identified morphological renal abnormalities such as hydronephrosis, shrunken and obstructed kidneys. This correlation underscores the potential utility of 68Ga-PSMA imaging as a valuable tool for assessing kidney morphology as an alternative to renogram split function in clinical practice.
medicine, general & internal
What problem does this paper attempt to address?
The paper primarily explores the correlation and potential substitutability of two different renal function assessment methods in evaluating renal function in patients with metastatic castration-resistant prostate cancer (mCRPC). The research background of the paper is that prostate cancer is one of the most common cancers in men, especially with a higher incidence and more severe condition in African men. For mCRPC patients, conventional treatments such as chemotherapy and immunotherapy have limited efficacy. However, in recent years, radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) has shown better efficacy. Since PSMA is also expressed in the proximal renal tubular cells, it may lead to the accumulation of radioactive drugs in the kidneys, causing potential renal toxicity. Therefore, before receiving PSMA-targeted RLT, a 99mTc-MAG3 renal scan is usually performed to assess baseline renal function and exclude the possibility of renal obstruction. The main objective of the study is to compare the correlation between split renal function (SRF) derived from 68Ga-PSMA positron emission tomography/computed tomography (PET/CT) and SRF derived from 99mTc-MAG3 renal scan, and to explore the feasibility of the former as an alternative to the latter. The research methods include a retrospective cross-sectional study of 28 mCRPC patients who received 177Lu-PSMA-617 RLT treatment. The function of both kidneys was assessed using 68Ga-PSMA PET/CT and 99mTc-MAG3 renal scan, and statistical analysis was performed to compare the SRF results obtained by the two methods. The study results showed a highly significant correlation (p<0.001) between 68Ga-PSMA PET/CT and 99mTc-MAG3 renal scan, with a correlation coefficient as high as 0.957. This indicates that the SRF results obtained by the two methods are very close, and 68Ga-PSMA PET/CT can be used as an effective alternative method for assessing patients' renal function. Additionally, both imaging techniques demonstrated good consistency in identifying renal morphological abnormalities. In conclusion, the study suggests that split renal function assessment based on 68Ga-PSMA PET/CT can be used as an alternative method for renal function assessment before RLT in mCRPC patients, thereby reducing the number of additional visits and radiation exposure for patients.